Skip to main content
. 2016 Mar 4;7(14):18694–18704. doi: 10.18632/oncotarget.7909

Figure 2. Suppression of PLX4032-resistant B-Raf(V600E) cell types by MEDICA.

Figure 2

(A) EGF- and HGF-induced resistance to PLX4032. Mean ± SD. *Significant as compared to control. (B) Suppression of PLX4032-resistant B-Raf(V600E) cell types by MEDICA. Mean ± SD. #Significance of added cytokine as compared to its absence. *Significant as compared to respective control. (C) Suppression of EGF- and HGF-induced phosphorylation of EGFR, ErbB2/HER, MET, Erk and Akt by MEDICA. Representative blots. (D) Suppression of gp130, IL6- and HGF-induced phosphorylation of STAT3, and constitutive STAT3 by MEDICA. Representative blots. (E) Suppression of transfected STAT3 reporter by MEDICA (HT29 cells). Mean ± SE. #Significant as compared to control. *Significant as compared to control IL-6.